SCHEMBL21964114

SCHEMBL21964114

CC(=O)c1ccc(C=NS(=O)(=O)c2ccc(C)cc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.62
▸ POLB P06746 2/20 0.62
▸ MAPT P10636 2/20 0.50
▸ HPGD P15428 1/20 0.50
▸ LMNA P02545 3/20 0.47
▸ GAA P10253 1/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ STAT3 P40763 1/20 0.47
▸ STAT1 P42224 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ KMT2A Q03164 2/20 0.46
▸ MEN1 O00255 1/20 0.45
▸ ALOX12 P18054 1/20 0.45
▸ PTGS2 P35354 3/20 0.44
▸ ATM Q13315 1/20 0.44
▸ AKR1C3 P42330 1/20 0.43
▸ PTGS1 P23219 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21964113 1.00 ALDH1A1 (0.62) ALDH1A1POLBMAPTHPGDLMNA
SCHEMBL21964173 0.88 ALDH1A1 (0.62) ALDH1A1POLBLMNAGAASMN1; SMN2
SCHEMBL21964172 0.88 ALDH1A1 (0.62) ALDH1A1POLBLMNAGAASMN1; SMN2
SCHEMBL10073012 0.87 ALDH1A1 (0.78) ALDH1A1POLBLMNAGAANPC1
SCHEMBL16802983 0.87 ALDH1A1 (0.78) ALDH1A1POLBLMNAGAANPC1
SCHEMBL307938 0.87 ALDH1A1 (0.78) ALDH1A1POLBLMNAGAANPC1
SCHEMBL23824893 0.82 ALDH1A1 (0.59) ALDH1A1POLBMAPTHPGDLMNA
SCHEMBL14446284 0.81 PKM (0.61) ALDH1A1POLBLMNAGAANPC1
SCHEMBL12516171 0.80 ALDH1A1 (0.68) ALDH1A1POLBLMNAGAANPC1
SCHEMBL12444212 0.80 ALDH1A1 (0.68) ALDH1A1POLBMAPTLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220098155-A1 NOVEL PATHWAY FOR THE SYNTHESIS OF DIAZIRINES, THAT MAY OR MAY NOT BE ENRICHED IN NITROGEN-15 INSTITUT NATIONAL DES SCIENCES APPLIQUEES DE ROUEN (INSA) (FR) 2022-03-31 — — US disclosed
EP-3880662-A1 NOVEL PATHWAY FOR THE SYNTHESIS OF DIAZIRINES, THAT MAY OR MAY NOT BE ENRICHED IN NITROGEN-15 Universite de Rouen Normandie (FR) 2021-09-22 — — EP disclosed
WO-2020099596-A1 NOVEL PATHWAY FOR THE SYNTHESIS OF DIAZIRINES, THAT MAY OR MAY NOT BE ENRICHED IN NITROGEN-15 UNIVERSITE DE ROUEN NORMANDIE (FR) 2020-05-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220098155-A1 NOVEL PATHWAY FOR THE SYNTHESIS OF DIAZIRINES, THAT MAY OR MAY NOT BE ENRICHED IN NITROGEN-15 SSTR5, SLC6A15, SLC1A5 ALDH1A1 2836/4885POLB 2496/4885MAPT 3844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback